Lyme disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  Ceftriaxone for Post-Treatment Lyme Disease

  NCT06785402· Hackensack Meridian Health· Updated 18 May 2026

  “Enrollment challenges”Registry text, quoted unchanged. Source

• Terminated

  Symptomatic Management of Lyme Arthritis

  NCT04038346· Desiree Neville, MD· Updated 17 Nov 2025

  “Study with overlapping patient population”Registry text, quoted unchanged. Source

• Withdrawn

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Lyme Disease

  NCT04148222· ProgenaBiome· Updated 5 Jun 2025

  “Company focus shifted”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation and Follow-up of People With Tick-borne Diseases

  NCT04318925· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 18 Nov 2023

  “No recruitment”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• The Precision Mito- Mito Map COMPASS Study

  NCT07856121· AI Agent Vault, Inc. d/b/a Precision Mito· Source

• Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

  NCT04801420· Pfizer· Source

• An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Pfizer· Source

• Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

  NCT05634811· Pfizer· Source

• A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

  NCT07226882· Pfizer· Source

• A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

  NCT07500506· Pfizer· Source

• Borrelia B-cell Diagnostics

  NCT06045416· University Children's Hospital, Zurich· Source

• Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

  NCT06611111· State University of New York - Upstate Medical University· Source

• Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

  NCT04806620· Brain Inflammation Collaborative· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.